Paul Davey, MD
Otolaryngology · Riverhead, NYNPI 1831189810
Payments from drug & device makers
Across 25 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$143
- Novartis$95
- Kaleo, Inc.$68
- Inspire Medical Systems, Inc.$52
- Phathom Pharmaceuticals, Inc.$25
- Stryker$24
- plus $138 from 7 others
What the payments were for
- Food & beverage$545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 6 | $143 |
| Novartis | 5 | $95 |
| Kaleo, Inc. | 3 | $68 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Stryker | 1 | $24 |
| Medtronic | 1 | $24 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $24 |
| LEO Pharma Inc. | 1 | $24 |
| Alk-abello, Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| CSL Behring | 1 | $14 |
How this compares
$545 in reported general payments places this provider in the 35th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 528 | $13,555 |
| Famotidine | 545 | $13,214 |
| Mometasone Furoate | 20 | $3,593 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 33 | $3,236 |
| Ipratropium Bromide | 75 | $3,002 |
| Fluocinolone Acetonide Oil | 75 | $2,802 |
| Sucralfate | 62 | $1,800 |
| Mupirocin | 255 | $1,788 |
| Cefdinir | 63 | $1,217 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $1,121 |
| Omeprazole | 78 | $935 |
| Pantoprazole Sodium | 49 | $824 |
| Doxycycline Hyclate | 46 | $571 |
| Azelastine Hcl | 19 | $276 |
| Ciprofloxacin Hcl | 14 | $267 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Riverhead
- Robert KellmanSyracuse$2.5M
- Anthony DelsignoreNew York$966K
- Roheen RaithathaNew York$882K
- Dennis KrausNew York$524K
- Ashutosh KackerNew York$387K
- Lawrence LustigNew York$383K
- Brett MilesNew York$368K
- Alfred Marc IloretaNew York$342K
- Nora PerkinsAlbany$315K
- Gavin SetzenAlbany$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.